vs
Esperion Therapeutics, Inc.（ESPR）与丰田北美（MPAA）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是丰田北美的1.0倍（$168.4M vs $167.7M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -9.9%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -5.9%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
丰田北美（TMNA）是丰田汽车旗下负责加拿大、墨西哥及美国全境业务的运营子公司，业务范围覆盖研发、生产制造、销售营销、售后及企业管理等板块，相关核心业务由TMNA统筹，部分板块由其他子公司及控股企业负责执行，公司总部位于得克萨斯州普莱诺，在肯塔基州乔治敦等多地设有分支机构。
ESPR vs MPAA — 直观对比
营收规模更大
ESPR
是对方的1.0倍
$167.7M
营收增速更快
ESPR
高出153.7%
-9.9%
两年增速更快
ESPR
近两年复合增速
-5.9%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $167.7M |
| 净利润 | — | $1.8M |
| 毛利率 | — | 19.6% |
| 营业利润率 | 50.6% | 5.0% |
| 净利率 | — | 1.1% |
| 营收同比 | 143.7% | -9.9% |
| 净利润同比 | — | -22.4% |
| 每股收益（稀释后） | $0.32 | $0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRMPAA
| Q4 25 | $168.4M | $167.7M | ||
| Q3 25 | $87.3M | $221.5M | ||
| Q2 25 | $82.4M | $188.4M | ||
| Q1 25 | $65.0M | $193.1M | ||
| Q4 24 | $69.1M | $186.2M | ||
| Q3 24 | $51.6M | $208.2M | ||
| Q2 24 | $73.8M | $169.9M | ||
| Q1 24 | $137.7M | $189.5M |
净利润ESPRMPAA
| Q4 25 | — | $1.8M | ||
| Q3 25 | $-31.3M | $-2.1M | ||
| Q2 25 | $-12.7M | $3.0M | ||
| Q1 25 | $-40.5M | $-722.0K | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | $-29.5M | $-3.0M | ||
| Q2 24 | $-61.9M | $-18.1M | ||
| Q1 24 | $61.0M | $1.3M |
毛利率ESPRMPAA
| Q4 25 | — | 19.6% | ||
| Q3 25 | — | 19.3% | ||
| Q2 25 | — | 18.0% | ||
| Q1 25 | — | 19.9% | ||
| Q4 24 | — | 24.1% | ||
| Q3 24 | — | 19.8% | ||
| Q2 24 | — | 17.2% | ||
| Q1 24 | — | 18.4% |
营业利润率ESPRMPAA
| Q4 25 | 50.6% | 5.0% | ||
| Q3 25 | -11.4% | 7.4% | ||
| Q2 25 | 8.6% | 10.7% | ||
| Q1 25 | -34.0% | 8.4% | ||
| Q4 24 | -6.4% | 9.4% | ||
| Q3 24 | -31.0% | 6.0% | ||
| Q2 24 | 3.5% | -3.8% | ||
| Q1 24 | 52.5% | 6.4% |
净利率ESPRMPAA
| Q4 25 | — | 1.1% | ||
| Q3 25 | -35.9% | -1.0% | ||
| Q2 25 | -15.4% | 1.6% | ||
| Q1 25 | -62.2% | -0.4% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | -57.2% | -1.4% | ||
| Q2 24 | -83.9% | -10.6% | ||
| Q1 24 | 44.3% | 0.7% |
每股收益（稀释后）ESPRMPAA
| Q4 25 | $0.32 | $0.09 | ||
| Q3 25 | $-0.16 | $-0.11 | ||
| Q2 25 | $-0.06 | $0.15 | ||
| Q1 25 | $-0.21 | $-0.03 | ||
| Q4 24 | $-0.14 | $0.11 | ||
| Q3 24 | $-0.15 | $-0.15 | ||
| Q2 24 | $-0.33 | $-0.92 | ||
| Q1 24 | $0.34 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $19.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $258.5M |
| 总资产 | $465.9M | $991.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRMPAA
| Q4 25 | $167.9M | $19.6M | ||
| Q3 25 | $92.4M | $17.7M | ||
| Q2 25 | $86.1M | $14.5M | ||
| Q1 25 | $114.6M | $11.3M | ||
| Q4 24 | $144.8M | $12.7M | ||
| Q3 24 | $144.7M | $12.3M | ||
| Q2 24 | $189.3M | $9.4M | ||
| Q1 24 | $226.6M | $15.8M |
股东权益ESPRMPAA
| Q4 25 | $-302.0M | $258.5M | ||
| Q3 25 | $-451.4M | $258.5M | ||
| Q2 25 | $-433.5M | $260.1M | ||
| Q1 25 | $-426.2M | $257.7M | ||
| Q4 24 | $-388.7M | $262.7M | ||
| Q3 24 | $-370.2M | $264.0M | ||
| Q2 24 | $-344.2M | $267.2M | ||
| Q1 24 | $-294.3M | $285.1M |
总资产ESPRMPAA
| Q4 25 | $465.9M | $991.3M | ||
| Q3 25 | $364.0M | $990.0M | ||
| Q2 25 | $347.1M | $973.4M | ||
| Q1 25 | $324.0M | $957.6M | ||
| Q4 24 | $343.8M | $949.5M | ||
| Q3 24 | $314.1M | $986.2M | ||
| Q2 24 | $352.3M | $978.0M | ||
| Q1 24 | $373.1M | $1.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $-8.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-8.6M |
| 自由现金流率自由现金流/营收 | — | -5.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.2% |
| 现金转化率经营现金流/净利润 | — | -4.63× |
| 过去12个月自由现金流最近4个季度 | — | $27.7M |
8季度趋势，按日历期对齐
经营现金流ESPRMPAA
| Q4 25 | $45.2M | $-8.2M | ||
| Q3 25 | $-4.3M | $21.9M | ||
| Q2 25 | $-31.4M | $10.0M | ||
| Q1 25 | $-22.6M | $9.1M | ||
| Q4 24 | $-35.0M | $34.4M | ||
| Q3 24 | $-35.3M | $22.9M | ||
| Q2 24 | $-7.2M | $-20.8M | ||
| Q1 24 | $53.8M | $-9.3M |
自由现金流ESPRMPAA
| Q4 25 | — | $-8.6M | ||
| Q3 25 | — | $20.8M | ||
| Q2 25 | — | $9.2M | ||
| Q1 25 | — | $6.2M | ||
| Q4 24 | — | $33.7M | ||
| Q3 24 | $-35.5M | $22.3M | ||
| Q2 24 | $-7.3M | $-21.3M | ||
| Q1 24 | $53.8M | $-9.8M |
自由现金流率ESPRMPAA
| Q4 25 | — | -5.2% | ||
| Q3 25 | — | 9.4% | ||
| Q2 25 | — | 4.9% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 18.1% | ||
| Q3 24 | -68.7% | 10.7% | ||
| Q2 24 | -9.9% | -12.6% | ||
| Q1 24 | 39.0% | -5.2% |
资本支出强度ESPRMPAA
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 1.5% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.3% | 0.3% | ||
| Q2 24 | 0.1% | 0.3% | ||
| Q1 24 | 0.1% | 0.3% |
现金转化率ESPRMPAA
| Q4 25 | — | -4.63× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 3.30× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 15.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | -6.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
MPAA
| Reportable Segment Aggregation Before Other Operating Segment | $156.3M | 93% |
| Other | $11.4M | 7% |
